A parent is shown two colorful brain images. One glows red near the front of the skull; the other looks cooler, quieter, apparently less active. The explanation arrives before the parent has time to ask a question: this is what ADHD looks like.
It is a powerful image. It may also be a misleading one.
A brain scan cannot currently diagnose ADHD in an individual. That answer is less dramatic than a picture, but more faithful to the science. Researchers have documented differences, on average, in brain structure, activity and connectivity among groups of people with and without ADHD. Those findings contribute to our understanding of a real neurodevelopmental condition. They do not amount to a reliable personal barcode that tells a clinician whether one particular child or adult has it.
The distinction matters for families looking for certainty, for clinicians evaluating complex presentations, and for a wider culture increasingly tempted to confuse sophisticated measurement with an accurate diagnosis.
The picture is real. The conclusion may not be.
Brain images are not photographs of a diagnosis. Most are computational reconstructions of particular kinds of measurements: anatomy, blood-oxygen changes associated with neural activity, or the movement of signals across networks. Many familiar heat maps are statistical comparisons between groups, produced through multiple processing steps.
That does not make the research artificial. It means the image is answering a specific scientific question, not necessarily the one a worried parent has brought into the consultation room.
Consider two questions:
Research: Do groups of people with ADHD, on average, show measurable differences from comparison groups?
Diagnosis: Does this scan tell us, with sufficiently reliable accuracy, whether this person has ADHD rather than another explanation for their difficulties?
An affirmative answer to the first does not establish an affirmative answer to the second.
The problem is overlap. People with ADHD are not neurologically identical to one another; people without ADHD are not neurologically identical either. A difference between group averages may coexist with many individuals whose measurements fall in the same range.
What MRI research actually found
One of the best-known large collaborations, the ENIGMA ADHD Working Group, analyzed structural MRI data from 1,713 people with ADHD and 1,529 comparison participants across 23 sites. The researchers reported small average volume differences in several subcortical regions and intracranial volume. The observed effects were most pronounced in children, while the case-control differences examined were not present in the adult group. The effect sizes were small, and symptom scores did not correlate with brain volume in that analysis.
These results are important because they emerged from a much larger and more coordinated investigation than many earlier studies. They also illustrate why the public interpretation must be restrained: a small statistical difference is not a diagnostic threshold, and a developmental pattern is not a universal brain type.
Another line of research examines functional MRI, including activity and connectivity in networks associated with attention, cognitive control and spontaneous thought. It can help scientists investigate hypotheses about regulation and variability. But there is no single accepted pattern that clinicians can examine on an individual scan and pronounce ADHD present or absent.
Neither a relatively typical-looking MRI nor an unusual-looking MRI settles the diagnosis.
The useful scientific achievement here is not the discovery of a neurological mugshot. It is a growing, revisable account of how many interacting brain systems may contribute to attention, inhibition, motivation and self-regulation.
Why a promising AI classifier is not yet a medical test
Machine-learning studies can report striking results. An algorithm is trained on collections of scans and learns patterns that distinguish people labeled ADHD from comparison participants. In carefully selected samples, performance can look impressive.
But a classifier trained to separate two research groups faces a comparatively tidy problem. A clinician faces a much messier one. The person seeking help may have sleep deprivation, anxiety, depression, trauma exposure, learning difficulties, autism, epilepsy or more than one condition. Some have ADHD as well. Some have impairing attention difficulties without meeting ADHD criteria.
An imaging model therefore needs to prove itself not merely against healthy controls, but against the range of people who actually arrive at clinics. It must also work across scanners, hospitals, ages, sexes, other conditions and demographic contexts that were not conveniently represented in its training data.
An American Academy of Pediatrics systematic review published in Pediatrics in 2024 examined diagnostic tools for children and adolescents. It included 19 neuroimaging studies, with widely variable accuracy estimates. The reviewers found that neuroimaging algorithms generally lacked independent prospective replication and that several studies used pre-existing data to separate ADHD from typically developing controls rather than other clinical populations.
A separate systematic review of 100 individualized ADHD prediction models, published in 2024, found that only 7% had external validation, none had been implemented in clinical practice, and most were not assessed as low risk of bias.
This is not an argument against AI in neuroscience. It is an argument for the standards medical AI must meet before real people are asked to trust it.
The clinical question nobody should skip
Imagine a tool that correctly identifies many people with ADHD in a curated research sample but also flags a substantial proportion of people referred for anxiety or sleep problems. The accuracy headline might still sound impressive, yet the consequences would be serious: unnecessary labels for some, missed conditions for others, and false reassurance when the result is negative.
Sensitivity, specificity, calibration, independent replication and real-world clinical utility all matter. So does a less glamorous question: Does the tool actually improve decisions and outcomes compared with a careful assessment without it?
Until there is convincing evidence that it does, an elegant algorithm remains a research instrument or candidate aid—not a substitute for clinical reasoning.
What about EEG, brain mapping and FDA-cleared devices?
A scan and an EEG are not the same thing. MRI uses magnetic fields to examine anatomy or blood-oxygen-related signals. EEG records electrical activity from electrodes on the scalp. Both have generated ADHD-related research.
The distinction becomes important when commercial descriptions blur the two.
In 2013, the US Food and Drug Administration authorized the NEBA system, which uses an EEG theta/beta ratio in people aged 6–17 as an aid to clinical assessment. Its stated indication was not standalone diagnosis: it was to provide confirmatory support after an evaluation or help a clinician decide whether further testing was needed.
That history should not be converted into the claim that the FDA approved a universal brain test for ADHD. Regulatory authorization for a narrowly specified adjunct is not the same as evidence that all EEG maps, brain scans or proprietary indices can reliably confirm the condition.
The broader evidence remains cautious. A 2025 review in World Psychiatry concluded that existing biomarkers—including neuroimaging and EEG—do not have adequate diagnostic predictive power for routine ADHD assessment, while acknowledging that such investigations may be appropriate for specific differential-diagnostic questions.
There is another useful distinction. In England, NICE recommends QbTest as an option to assist clinical assessment for ages 6–17, not to replace it. QbTest measures performance on a computerized attention task alongside movement tracking; it is not a brain scan. Its limited, adjunctive role illustrates how an objective measurement can sometimes help clinicians without acquiring the authority to make a diagnosis by itself.
If a scan cannot diagnose ADHD, what can?
It is easy to hear the absence of a scan-based test as a weakness in the diagnosis. That would be the wrong conclusion.
ADHD is assessed clinically because its defining features concern developmental patterns of attention, activity, impulsivity and their consequences across life—not a currently validated anatomical marker.
For children, an evaluation draws on information from the child and caregivers, school or other relevant settings, the developmental history, and the degree to which difficulties interfere with functioning. For adults, an evaluator considers the current presentation together with childhood history, changes over time, compensatory strategies and real-world impairment. In all ages, the clinician must consider other possible explanations and conditions that may coexist.
The US Centers for Disease Control and Prevention states that there is no single test to diagnose ADHD. NICE similarly calls for a full clinical and psychosocial assessment, developmental and psychiatric history, observer reports and a qualified professional's judgment.
This does not mean every symptom checklist is sufficient. Rating scales can organize reports; they cannot by themselves establish when difficulties began, what happens in different settings, whether alternative explanations are more plausible, or what support is needed.
Nor does it mean scans have no medical role. If a clinician has reason to suspect another neurological condition, imaging or other investigations may be appropriate for that particular question. The point is that routine imaging is not an ADHD confirmation test.
Five questions that tell more than a colorful scan
A family or adult seeking an assessment can reasonably ask:
Which diagnostic criteria and developmental history are being considered?
How will difficulties and impairment be examined across relevant settings?
What other conditions or contextual factors could explain—or coexist with—the symptoms?
What do questionnaires, interviews or computerized tasks add, and what are their limitations?
How will the findings translate into a useful explanation and support plan?
These questions do not promise instant certainty. They make the reasoning visible—and therefore open to scrutiny, correction and clinical responsibility.
Two opposite myths about ADHD and the brain
The first myth says: If ADHD is neurological, we should be able to see it on a scan.
This treats biology as if it must produce a unique image before a condition can be taken seriously. Biology is often distributed, variable and influenced by development and context. A condition can have meaningful biological underpinnings without an individually diagnostic picture.
The second myth says: If we cannot see ADHD on a scan, perhaps it is not real.
This reverses the same error. The limits of a particular measuring instrument do not decide the reality of an individual's difficulties. Clinical validity requires converging evidence, careful definitions, reliability and an understanding of what the assessment is meant to explain.
The more serious debate concerns how confidently neuroscience can identify mechanisms, explain different presentations, predict outcomes and improve support. That debate is productive. Turning a suggestive brain map into a personal verdict is not.
The books behind the question: understanding biology without overclaiming diagnosis
Two Learning Coach books approach this divide from different directions.
The Excited Brain: The Neuroscience of ADHD and the Biology of Focus is an accessible exploration of attention, brain networks, chemistry, development, sleep, movement and behavior. Its central editorial contribution is to move the conversation away from moral judgment—laziness, indiscipline, lack of effort—and toward questions about how regulation works. That is an invitation to understand mechanisms, not an endorsement of scan-based diagnosis.
Assessing ADHD The Right Way: A Complete Theoretical and Practical Training Manual for Therapists addresses the other side of the problem: how qualified professionals organize interviews, developmental evidence, functional impairment, differential diagnosis, clinical formulation and feedback. Its premise is that a tool supports judgment; it does not replace it.
Read together, the books suggest a distinction that deserves to be at the center of public discussion: explaining ADHD biologically and diagnosing it clinically are complementary tasks, not interchangeable ones.
The first task asks how the brain may contribute to attention and behavior. The second asks whether an individual meets established criteria, what else is relevant, and what responsible support should follow.
Books & Ideas is published by Learning Coach, which also publishes these titles. This is an affiliated editorial analysis, not an independent third-party review. The books' arguments should be read alongside—rather than in place of—the clinical guidance and research cited below.
The future is better evidence, not brighter images
Could neuroscience eventually contribute a reliable diagnostic biomarker or a clinically useful multimodal decision aid? Certainly that remains a legitimate research goal. Better-designed studies, diverse participants, independent validation and comparisons with real clinical alternatives may change practice.
But progress should be judged by improved decisions, fair performance across populations, reduced diagnostic error and better outcomes—not by the visual sophistication of the technology.
For now, the most honest answer to the headline question remains clear. A scan may help scientists investigate ADHD; it does not tell a person who they are.
The goal of assessment is not to obtain the most impressive picture of a brain. It is to reach the most defensible understanding of a life.
Evidence and further reading
Centers for Disease Control and Prevention — Diagnosing ADHD. Guidance on the multi-step clinical assessment process and differential considerations.
NICE guideline NG87 — ADHD: diagnosis and management. Clinical assessment requirements and the place of qualified professional judgment.
Hoogman et al., 2017 — Subcortical brain volume differences of participants with ADHD across the lifespan. ENIGMA collaboration; structural MRI group comparisons and small effects.
American Academy of Pediatrics, 2024 — Tools for the Diagnosis of ADHD in Children and Adolescents: A Systematic Review. Appraisal of diagnostic tools including neuroimaging and EEG.
Individualized prediction models in ADHD: a systematic review and meta-regression, 2024. Validation, risk of bias and readiness for clinical application.
Cortese et al., 2025 — ADHD in adults: evidence base, uncertainties and controversies. Review of biomarkers and limitations of ancillary tests.
US FDA — NEBA decision summary. Specific age range and adjunctive indication for an EEG-based aid.
NICE HTG729 — Digital technologies for assessing ADHD. QbTest and the distinction between objective aids and full clinical assessment.
Editorial and medical note: This article is for public education. It is not an individual assessment, medical recommendation or substitute for professional care. Diagnostic practices should follow applicable local guidelines and professional qualifications.
